AASLD

Pharmasset to Webcast an Investor Event from the AASLD Meeting

PRINCETON, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Sunday, November 2, 2008 starting at 5:30 PM PT. During this webcast, management ...

Positive Results From Peregrine Pharmaceuticals' Bavituximab Phase l HCV Trial Presented at AASLD Meeting

- Bavituximab Appeared Generally Safe and Well Tolerated at All Doses Tested - - Signs of Anti-viral Activity Seen at All Dose Levels - - Exploratory Analysis of Cytokine Profile Following Treatment Supports Proposed Immunomodulatory Mechanism ...

William F. Balistreri, M.D., honored with Distinguished Service Award by AASLD

Cincinnati, February 5, 2008 William F. Balistreri, MD, Editor of The Journal of Pediatrics, has been honored with the American Association for the Study of Liver Diseases (AASLD) 2007 Distinguished Service Award, recognizing his sustained commitment and contribution to the AASLD as well as to the...

Publishers John Wiley & Sons Enter Into An Agreement With NASPGHAN And AASLD

Global publisher John Wiley & Sons, Inc., confirms their plans to go into a partnership with NASPGHAN and AASLD for providing subscriptions of their journal.// International publisher John Wiley & Sons, Inc., had announced on the 6th of September their plans of a new agreement with the North ...

Radiofrequency treatment better than ethanol injection for small liver tumors

...an Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience ( www.interscience.wiley.com ). aasld guidelines recommend PEI as a safe and highly effective treatment for small hepatocellular carcinomas and say it is the standard against which new the...

No Difference in Rate of Survival for Children of Different Races Undergoing Liver Transplantation, but Long-Term Results Not as Good for African-American Adults

... after pediatric liver transplantation 2. Relationship between recipient race and transplant predictors of outcome following liver transplantation aasld is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent ...

Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study

... Association for the Study of Liver Diseases (AASLD), to be held in San Francisco, California. Further preclinical data on ANA598 will be presented at aasld in two additional poster presentations on November 4. Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submis...

Bayer and Onyx Launch Educational Program to Raise Awareness About Liver Cancer and Its Risk Factors

...h. More than 650 qualified scientists and physicians have pursued careers in liver disease research and treatment as a result of receiving the ALF and aasld grants early in their careers. No other voluntary organization in the nation provides a voice for the 30 million Americans with liver disease. The A...

Why Are Some Veterans Who Are Coinfected With Hepatitis C and HIV More Likely to Be Treated for HCV Than Others?

...CV care." Abstract title: Patient, provider, and facility characteristics of HCV antiviral treatment among US veterans with HCV-HIV coinfection. aasld is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent ...

Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children

... concluded Dr. Feldstein. Abstract title: The natural history of nonalcoholic fatty liver disease in children: A follow-up study up to 20 years. aasld is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent ...

AASLD in Medical Technology

Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008

Nearly 90 percent of patients achieve undetectable viral load in Phase IIa trial within 28 days of combined treatment with standard of care SAN FRANCISCO, Nov. 1 /PRNewswire/ -- New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by...

Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C

- Albuferon requires half as many injections as standard therapy, and demonstrated at least comparable efficacy, comparable safety and less impairment of quality of life on treatment - - Final results of Phase 2b trial of Albuferon in treatment-naive hepatitis C patients presen...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... Interim results of HCV SPRINT-1 study presented at aasld annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov. 1 /PRNewswir...

Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers

...eers", at 1:00 p.m. PST on Monday, November 3. ANA598 Preclinical Data at aasld Meeting In addition to the results of the Phase I healthy volunteer study...s is presenting additional data on the preclinical profile of ANA598 at the aasld Meeting on Tuesday, November 4. -- In a poster titled "In Vitro Studies D...

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

...- November 4, 2008. Abstracts can be viewed at the aasld website at http://www.aasld.org . ANA598 Progra...dies during 2009. ANA598 Data to be Presented at aasld Meeting Anadys will present data on ANA598 durin..., which are summarized below, can be viewed at the aasld website at http://www.aasld.org . Anadys will p...

Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy

...lts were presented yesterday in Boston at the 58th aasld Annual Meeting in Boston. (Logo: http://www.news...y, the Company announced the full presentations at aasld of efficacy and safety data, and quality-of-life d...y's web site at http://www.hgsi.com . To view the aasld oral presentation reporting results of the Phase 2...

Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C

... results are being presented this week at the 58th aasld Annual Meeting in Boston. In two additional press ...y, the Company announced the full presentations at aasld of efficacy and safety data from the Phase 2b tria...y's web site at http://www.hgsi.com . To view the aasld oral presentation reporting results of the Phase 2...

Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks

...h hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies." Antiviral Activity and Safety Results Being Presented at aasld The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to eval...

R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients

...ance with the conference press embargo guidelines, no additional data will be available for this study until the scientific abstracts are published by aasld on October 1, 2007. Dr. Rajender Reddy, Professor of Medicine and Surgery in the Division of Gastroenterology at the University of Pennsylvania and a...

AASLD in Biological Technology

Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008

Findings Include 80% SVR Rate with Nitazoxanide-Based Combination Therapy and New Insights into Mechanism of Action of Nitazoxanide SAN FRANCISCO, Nov. 3 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in...

Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco

Company Also Announces Completion of Enrollment in U.S. Phase II Study of Nitazoxanide in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 TAMPA, Fla., Oct. 28 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced the presentation of stu...

InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting

- Results of Phase 1 clinical studies support advancement to Phase 2 - - Results of in-vitro study of ITMN-191 with Roche polymerase inhibitors - BRISBANE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that four abstracts from clinical and in-vit...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... of all seven cohorts of the INFORM-1 study at the aasld meeting on November 3." Results for the ...residential Plenary Session III (#193) at the 2009 aasld meeting at 8:00 a.m. on November 3. The company a...been accepted for poster presentations at the 2009 aasld meeting, also on November 3. ...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

...0 million payment to InterMune) Summer 2009 -- Presentation of additional cohorts of INFORM-1 at aasld Q4, 2009 * -- Rapid Viral Response (RVR) data from Phase 2b (12-week regimen) ...

InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights

...hase 2b initiation by Roche ($20 million payment to InterMune) Summer 2009 -- Presentation of all cohorts of INFORM-1 at aasld Q4, 2009 * -- Rapid Viral Response (RVR) data from Phase 2b (12-week regimen) Q4 '09 or Q1 '10 ...

Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health

...valuated in larger trial." Abstract title: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis (NASH) aasld is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent ...

InterMune Reports Second Quarter 2008 Financial Results and Business Highlights

...tandard of care therapy." Mr. Welch continued, "The next six months will be a very rich period in terms of data and milestones for InterMune. At the aasld meeting in late October, we expect to present the results of our two completed clinical studies of ITMN-191 as well as the results of non-clinical stu...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008

... safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. -- In November 2007 at the prestigious aasld meeting, Peregrine reported final results from its Phase Ib study of bavituximab in patients with chronic HCV infection. Bavituximab appeared generall...

The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6

...C, whereas liver cancer is one of the few cancers growing in incidence. An aasld President's press conference highlighting key abstracts and issues presente...tions: November 3-6 -- Oral Presentations: November 4-6 Please contact aasld at 703-299-9766 for information about the above presentations, or to receiv...